When was Nucle AI founded?

Nucle AI was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Nucle AI located?

Nucle AI is headquartered in Chicago, United States.

Who is the current CEO of Nucle AI?

Avi Veidman of Nucle AI. They have also founded 1 company.

How many employees does Nucle AI have?

As of Sep 30, 2026, the latest employee count at Nucle AI is 68.

Is Nucle AI a funded company?

Nucle AI is a funded company, having raised a total of $60M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 05, 2018.

When was the latest funding round of Nucle AI?

Nucle AI's latest funding was a $***** Series B round on Apr 03, 2024, with participation from 1 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.88B in funding in 2026 to date.

Where does Nucle AI rank among its competitors?

Nucle AI ranks 5th amongst 262 active competitors, of which 77 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was DeepWise, which secured an undisclosed amount in Jun, 2026.

Who are the top competitors of Nucle AI?

Nucle AI's top competitors include PathAI, Aiforia and Techcyte. Among them, DeepWise secured the most recent funding round in June, 2026.

Nucle AI - 2026 Company Profile, Team, Funding & Competitors

Nucle AI is a series B company based in Chicago (United States), founded in 2017 by Avi Veidman. It operates as an AI-assisted platform for image analysis. Nucle AI has raised $60M in funding from investors like Debiopharm, Grove Ventures and M Ventures. The company has 262 active competitors, including 77 funded and 13 that have exited. Its top competitors include companies like PathAI, Aiforia and Techcyte.

Company Details

AI-assisted platform for image analysis. The platform enables researchers to analyze and predict the tissue and cell architecture from pathology slides. It helps with the discovery of pathology-based spatial biomarkers.

Website: nucleai.ai
Social
Email ID: *****@nucleai.ai

Key Metrics

Founded Year

2017

Location

Chicago, United States

Stage

Series B

Total Funding

$60M in 4 rounds

Latest Funding Round

Series B, Apr 03, 2024, $*****

Investors

Debiopharm & 10 more

Ranked

5^th among 262 active competitors

Employee Count

68 as on Sep 30, 2026

Similar Companies

PathAI & 298 more

View Nucle AI's full profile

Nucle AI is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Nucleai Inc CIN: 86-1683979 , United States, Active		-	9 (As on Dec 31, 2023)	-

Nucle AI has raised a total funding of $60M over 4 rounds. Its first funding round was on Mar 05, 2018. Its latest funding round was a Series B round on Apr 03, 2024 for $*****. 1 investor participated in its latest round. Nucle AI has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Nucle AI:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2024	4769514	Series B	9729025	2873779	7565787	3472765
Mar 22, 2022	9419311	Series B	7766003	6553205	4782517	Debiopharm & 3 more
Jul 07, 2020	4667237	Series A	3579864	4651317	Debiopharm	Grove Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Nucle AI's funding rounds and investors

The founders of Nucle AI is Avi Veidman. Avi Veidman is the CEO of Nucle AI.

Here are the details of Nucle AI's key team members:

Avi Veidman: Co-Founder & CEO of Nucle AI and founder of 1 other company.
Contact Info: 2 email addresses

View details of Nucle AI's Founder profiles and Board Members

Nucle AI's employee count trend

Nucle AI has 68 employees as of Sep 26. Here is Nucle AI's employee count trend over the years:

Uncover Nucle AI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nucle AI include PathAI, Aiforia and Techcyte. Here is the list of Top 10 competitors of Nucle AI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, General Atlantic & 22 others	72/100
2nd	Aiforia 2014, Helsinki (Finland), Public	Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas	$23M	Ascend Capital Partners, Businessfinland & 8 others	66/100
3rd	Techcyte 2014, Orem (United States), Series B	Artificial intelligence (AI) based image analysis platform for pathologists	$50.4M	ARUP Laboratories, Zoetis & 2 others	62/100
4th	Proscia 2014, Philadelphia (United States), Acquired	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Triangle Peak Partners, TEDCO & 22 others	62/100
5th	Nucle AI 2017, Chicago (United States), Series B	AI-assisted platform for image analysis	$60M	Vertex Ventures Israel, Sanofi Ventures & 9 others	61/100
6th	Aignostics 2018, Berlin (Germany), Series B	Developer of artificial intelligence software for biomedical image analysis applications	$53.9M	Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund ... & 9 others	61/100
7th	DeepWise 2017, Beijing (China), Series D	Developer of AI-based radiology image solutions primarily for cancer diagnosis	$115M	Legend Capital, CICC Capital & 18 others	59/100
8th	Mindpeak 2017, Hamburg (Germany), Series A	Provider of AI-based pathological analysis platform	$18.3M	IFB Innovationsstarter, ZEISS & 28 others	59/100
9th	NeoSoma 2019, Boston (United States), Series B	Provider of an AI-based image analysis and decision-making platform for neurooncologist	$10.2M	-	58/100
10th	Onc.ai 2020, San Carlos (United States), Series A	AI-based cancer treatment and diagnosis platform for healthcare providers	$31M	Accomplice, MassMutual & 12 others	57/100